Israel's leading VC fund, Peregrine Ventures, has completed a USD 2.2 million Series A financing round with OutSense, who intends to use the funds to continue developing technology to monitor health and prevent potentially life-threatening disease. OutSense's "proprietary technology includes screening for hidden blood in stool, which is an established early sign of colorectal cancer (CRC). The technology also monitors dehydration, urinary tract infections, constipation, and diarrhea, which are major causes for hospitalization of the elderly".
Peregrine Ventures is represented by Elie Sprung, Head of Hi-Tech and Venture Capital.
Read more about the financing round here.